View in EDS

Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patients.

Saved in:
Bibliographic Details
Title: Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patients.
Authors: van der Schalk TE; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium., Berkell M; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.; Molecular Pathology Group, Cell Biology & Histology, University, of Antwerp, Wilrijk, Belgium., Hottebeekx A; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.; Molecular Pathology Group, Cell Biology & Histology, University, of Antwerp, Wilrijk, Belgium., Timbermont L; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium., Tabor DE; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Lammens C; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium., Recanatini C; Julius Center for Health Sciences and Primary Care, Epidemiology of Infectious Diseases Group, University Medical Center Utrecht, Utrecht, The Netherlands., Ruzin A; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., DiGiandomenico A; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Jafri H; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Chastre J; Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France., Esser MT; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., François B; ICU department and Inserm CIC 1435 & UMR 1092, CHU Limoges, Limoges, France., Bonten MJM; Julius Center for Health Sciences and Primary Care, Epidemiology of Infectious Diseases Group, University Medical Center Utrecht, Utrecht, The Netherlands., Goossens H; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium., Kluytmans JAJW; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Oliver A; Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears, CIBERINFEC, Palma de Mallorca, Spain., Glupczynski Y; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium., Kumar-Singh S; Molecular Pathology Group, Cell Biology & Histology, University, of Antwerp, Wilrijk, Belgium., Malhotra-Kumar S; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium. surbhi.malhotra@uantwerpen.be.
Corporate Authors: ASPIRE-ICU study team, COMBACTE-MAGNET EVADE study group
Source: Npj antimicrobials and resistance [NPJ Antimicrob Resist] 2026 May 08; Vol. 4 (1). Date of Electronic Publication: 2026 May 08.
Publication Type: Journal Article
Journal Info: Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918804282606676 Publication Model: Electronic Cited Medium: Internet ISSN: 2731-8745 (Electronic) Linking ISSN: 27318745 NLM ISO Abbreviation: NPJ Antimicrob Resist Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42103940
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patients.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22van+der+Schalk+TE%22">van der Schalk TE</searchLink>; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.<br /><searchLink fieldCode="AU" term="%22Berkell+M%22">Berkell M</searchLink>; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.; Molecular Pathology Group, Cell Biology & Histology, University, of Antwerp, Wilrijk, Belgium.<br /><searchLink fieldCode="AU" term="%22Hottebeekx+A%22">Hottebeekx A</searchLink>; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.; Molecular Pathology Group, Cell Biology & Histology, University, of Antwerp, Wilrijk, Belgium.<br /><searchLink fieldCode="AU" term="%22Timbermont+L%22">Timbermont L</searchLink>; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.<br /><searchLink fieldCode="AU" term="%22Tabor+DE%22">Tabor DE</searchLink>; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Lammens+C%22">Lammens C</searchLink>; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.<br /><searchLink fieldCode="AU" term="%22Recanatini+C%22">Recanatini C</searchLink>; Julius Center for Health Sciences and Primary Care, Epidemiology of Infectious Diseases Group, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Ruzin+A%22">Ruzin A</searchLink>; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22DiGiandomenico+A%22">DiGiandomenico A</searchLink>; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Jafri+H%22">Jafri H</searchLink>; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Chastre+J%22">Chastre J</searchLink>; Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.<br /><searchLink fieldCode="AU" term="%22Esser+MT%22">Esser MT</searchLink>; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22François+B%22">François B</searchLink>; ICU department and Inserm CIC 1435 & UMR 1092, CHU Limoges, Limoges, France.<br /><searchLink fieldCode="AU" term="%22Bonten+MJM%22">Bonten MJM</searchLink>; Julius Center for Health Sciences and Primary Care, Epidemiology of Infectious Diseases Group, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Goossens+H%22">Goossens H</searchLink>; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.<br /><searchLink fieldCode="AU" term="%22Kluytmans+JAJW%22">Kluytmans JAJW</searchLink>; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Oliver+A%22">Oliver A</searchLink>; Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears, CIBERINFEC, Palma de Mallorca, Spain.<br /><searchLink fieldCode="AU" term="%22Glupczynski+Y%22">Glupczynski Y</searchLink>; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.<br /><searchLink fieldCode="AU" term="%22Kumar-Singh+S%22">Kumar-Singh S</searchLink>; Molecular Pathology Group, Cell Biology & Histology, University, of Antwerp, Wilrijk, Belgium.<br /><searchLink fieldCode="AU" term="%22Malhotra-Kumar+S%22">Malhotra-Kumar S</searchLink>; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium. surbhi.malhotra@uantwerpen.be.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22ASPIRE-ICU+study+team%22">ASPIRE-ICU study team</searchLink><br /><searchLink fieldCode="CA" term="%22COMBACTE-MAGNET+EVADE+study+group%22">COMBACTE-MAGNET EVADE study group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918804282606676%22">Npj antimicrobials and resistance</searchLink> [NPJ Antimicrob Resist] 2026 May 08; Vol. 4 (1). <i>Date of Electronic Publication: </i>2026 May 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Portfolio%22">Nature Portfolio </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9918804282606676 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2731-8745 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2227318745%22">27318745 </searchLink><i>NLM ISO Abbreviation: </i>NPJ Antimicrob Resist <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42103940
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s44259-026-00199-3
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patients.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: van der Schalk TE
      – PersonEntity:
          Name:
            NameFull: Berkell M
      – PersonEntity:
          Name:
            NameFull: Hottebeekx A
      – PersonEntity:
          Name:
            NameFull: Timbermont L
      – PersonEntity:
          Name:
            NameFull: Tabor DE
      – PersonEntity:
          Name:
            NameFull: Lammens C
      – PersonEntity:
          Name:
            NameFull: Recanatini C
      – PersonEntity:
          Name:
            NameFull: Ruzin A
      – PersonEntity:
          Name:
            NameFull: DiGiandomenico A
      – PersonEntity:
          Name:
            NameFull: Jafri H
      – PersonEntity:
          Name:
            NameFull: Chastre J
      – PersonEntity:
          Name:
            NameFull: Esser MT
      – PersonEntity:
          Name:
            NameFull: François B
      – PersonEntity:
          Name:
            NameFull: Bonten MJM
      – PersonEntity:
          Name:
            NameFull: Goossens H
      – PersonEntity:
          Name:
            NameFull: Kluytmans JAJW
      – PersonEntity:
          Name:
            NameFull: Oliver A
      – PersonEntity:
          Name:
            NameFull: Glupczynski Y
      – PersonEntity:
          Name:
            NameFull: Kumar-Singh S
      – PersonEntity:
          Name:
            NameFull: Malhotra-Kumar S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 08
              M: 05
              Text: 2026 May 08
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2731-8745
          Numbering:
            – Type: volume
              Value: 4
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Npj antimicrobials and resistance
              Type: main
ResultId 1